KPV

Published · Researched 2026-09-21

Overview

KPV (Lys-Pro-Val) is a tripeptide corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). It retains the parent hormone's anti-inflammatory activity without the melanocortin-receptor "message core" — in cell and animal models it enters cells via the PepT1 transporter and inhibits NF-κB and MAPK inflammatory signaling intracellularly, making it a research target for gut inflammation (IBD/colitis models), skin inflammation, and general inflammatory modulation. In 2026 it is a rising "longevity secret" staple sold as 10 mg lyophilized research vials, capsules, and in blends, and it gained major regulatory attention when the FDA's PCAC voted in July 2026 to recommend it for the 503A compounding Bulks List (vote 8–6; not approval, final decision pending).

Social standing

Overall pulse: rising fast, enthusiastic with a serious cautionary minority. KPV is the "quiet anti-inflammatory workhorse" of the peptide community in 2026 — less viral than LL-37 but with broader stack-integration and compounding-pharmacy momentum.

Platform-by-platform:

  • Instagram (primary): Educator explainers drive the narrative. @drkristi.sawicki (45K, PhD peptide educator, Aug 2026) gave the most cited regulatory breakdown: PCAC 8–6 vote for 503A Bulks List inclusion, 2008 gastroenterology study (PepT1-mediated NF-κB inhibition), 2017 nanoparticle colon-delivery study — explicitly "not FDA approval." @realdrbae / Dr. Jonathan Kaplan (July 2026) broke the PCAC news the day of the meeting: KPV + BPC-157 recommended for compounding, 5 more decisions pending; comments split between celebration and "I'll just continue to get mines at AminoWorx. No thx FDA." @bydrvali (1.8M verified, July 2026) included KPV as the "gut-immune axis whisperer" in a BPC-157/TB-500 anti-inflammatory stack protocol (medically monitored, lab-marker-dosed). @tonnyw202-style car creator (June 2026) positioned KPV for mast-cell stabilization, histamine intolerance, and IBS/IBD — comments report both benefits and one adverse case ("I had some reaction to KPV. GI issues, headaches flu like."). @thezunigas (July 2026) sold the gut angle with a DM-based sales funnel (Aura Biopharma promo codes in comments). @aaliyahancestralcoach (19K, Aug 2026) "KPV in under a minute" with a Woosh Labs promo code. Gemini Biotech's infographic circulates the typical community dose: 250–500 mcg, 1–2×/day, SC (OBSERVED, UNVERIFIED). A 2026 Tissue and Cell study on KPV and adipocytes sparked a "hugely underrated" wave (one reel creator stressed explicitly: "not a fat-loss peptide").
  • Facebook (strong): HNR LABS reel (Aug 2026 — 1.9K likes, 270 comments): "KPV it shuts inflammation off at the source." Comments are dominated by sourcing questions (Uthers Research Factory, Amino Science Labs, Nu-pep.com, UK suppliers named), an aggressive FDA-distrust thread ("the FDA is compromised by Big Pharma and therefore LIES"), personal testimonials ("I've been on KPV for a few weeks. My body feels less inflamed!"), and autoimmune-flare warnings. Rush Pharmacy FB reel (Alex Spinoso, Aug 2026): compounding-pharmacy marketing for KPV, commenter pushback "Lotta claims. Show the human data." MarketWatch carousel (July 2026) covered the PCAC meeting neutrally: advisers voted yes for BPC-157, KPV, TB-500, MOTS-C; no on emideltide (6-7-1); yes on semax (8-5-1) and epitalon (7-4-1).
  • Threads: thin item-specific presence; general peptide-inflammation threads surfaced (e.g., "Which peptide is for inflammation?" — 114 likes, 67 replies) without KPV-specific evidence. Flagged as weak.

Viral moments: the July 23, 2026 PCAC meeting was the breakout regulatory moment, covered same-day by Dr. Kaplan and MarketWatch.

Recurring praise: GI inflammation/IBD anecdotes, skin (eczema, psoriasis) reports, arthritis pain reduction, "less inflamed" general testimonials, mast-cell/histamine claims, stacks with BPC-157 and retatrutide.

Recurring complaints / failure modes: (1) no human clinical trials — the dermatologist @drkaranslal (May 2026) posted a cautionary reel after a personal trial with "neither benefit nor harm," warning people are injecting KPV on mouse/cell data alone; (2) one GI/headache/flu-like adverse anecdote; (3) autoimmune-flare warnings; (4) relentless vendor spam (spartanlab.shop) drowning threads; (5) DM-based sales funnels with no accountability.

Representative quotes (attributed):

  • "I've been on KPV for a few weeks. My body feels less inflamed!" — Facebook commenter on the HNR LABS KPV reel, Aug 2026
  • "Lotta claims. Show the human data" — Facebook commenter on Rush Pharmacy's KPV reel, Aug 2026
  • "I take it for my GI inflammation but this is fascinating" — Instagram commenter on the KPV fat-cell-study reel, Aug 2026
  • "I had some reaction to KPV. GI issues, headaches flu like." — Instagram commenter on the KPV mast-cell reel, June 2026
  • "KPV is the JAM!" — Instagram commenter on @thezunigas' KPV gut reel, July 2026
  • "I'll just continue to get mines at AminoWorx. No thx FDA" — Instagram commenter on Dr. Kaplan's PCAC-news reel, July 2026
  • "the FDA is compromised by Big Pharma and therefore LIES" — Facebook commenter on the HNR LABS KPV reel (illustrates the distrust current, not an evidentiary claim)

Social validation

Tier 2 — strong evidence on 2 of 3 platforms: Instagram (owner/educator content, high engagement) and Facebook (reels + group-adjacent sourcing discussion). Threads presence is thin and unspecific to KPV — flagged.

Named sources and what each proves:

Key specs table

Property Value
Amino acid sequence H-Lys-Pro-Val-OH (KPV; α-MSH residues 11–13)
Molecular weight ~342.43 g/mol
Molecular formula C16H30N4O4
CAS 67727-97-3 (most commonly listed; conflicting CAS numbers appear on some vendor pages — 64790-08-5, 79147-07-0, and an N-acetyl variant at 84012-26-0 on Umbrella Labs. Treat vendor CAS discrepancies as UNVERIFIED/conflicting)
Mechanism (as studied) PepT1-mediated cellular entry → intracellular NF-κB and MAPK inhibition → reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Does not act through melanocortin receptors (lacks the His-Phe-Arg-Trp message core)
Available forms 10 mg lyophilized vials (standard); 2 mg vials; capsules (e.g., 60 × 500 mcg); blends (CLO, KLOW with GHK-CU/BPC-157/TB-500); nasal spray/oral discussed in community
Community-reported dosing (OBSERVED only, UNVERIFIED) 250–500 mcg 1–2×/day SC (Gemini Biotech infographic, community-circulated); evening dosing in stacks (Dr. Vali protocol); oral/nasal routes discussed with no standardized dosing. All anecdotal

Pricing (observed 2026-09-20)

What's included / what's needed

  • Included: one lyophilized KPV vial (commonly 10 mg) with vendor COA link; capsule bottles where sold.
  • Needed (per community practice, reported neutrally): bacteriostatic water, sterile syringes, alcohol wipes; refrigerated/frozen storage (−20 °C long-term per vendors). Licensed Peptides lists −20 °C storage.

Support reality

  • Vendor support reputation: not well documented; discussion is procurement-focused. Named community-mentioned vendors: Aura Biopharma (with promo codes), Strada Labs ("reliable and consistent" per one commenter), Uthers Research Factory, Amino Science Labs, Nu-pep.com, AminoWorx, Woosh Labs. These are commenter endorsements, not verified support reviews — treat as UNVERIFIED.
  • Counterfeit/fake concerns: moderate — the spam problem is bigger than the fake-product problem; coordinated spartanlab.shop spam floods threads.
  • COA/third-party testing: demanded by the informed minority; Maple Research Labs publishes a verifiable third-party report number (DBAV-KPV-10-062226); rejenesispeptides.com COA (ISO/IEC 17025 lab) for KPV 10 mg (99.71% purity, May 2026 batch). No independent cross-vendor purity survey found — UNVERIFIED.

Community verdict

KPV is 2026's rising anti-inflammatory staple: credible mechanistic story (PepT1/NF-κB), enthusiastic GI/skin anecdotes, and genuine regulatory momentum from the July 2026 PCAC 8–6 compounding vote — but zero human clinical trials, a loud cautionary minority (dermatologist personal trial: "neither benefit nor harm"), and comment sections dominated by sourcing questions and vendor spam rather than evidence. The "longevity secret" framing outruns the data.

Regulatory & safety status

  • Not an FDA-approved drug. Investigational research chemical, sold "for research use only / not for human consumption."
  • Key 2026 development: the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 on July 23, 2026 to recommend KPV for inclusion on the 503A Bulks List, which would allow licensed compounding pharmacies to produce it. This is NOT FDA approval; the final decision remains pending as of observation. BPC-157, TB-500, and MOTS-C received yes votes at the same meeting; emideltide was voted down; semax and epitalon voted yes.
  • Safety signals (observed data): no human safety studies (stated by physician creator and evidence summaries); one community report of GI issues/headache/flu-like symptoms; autoimmune-flare warnings in comments; no validated human dose. Causality for anecdotes is UNVERIFIED.

Image view breakdown

5/8 obtained. All real vendor/retailer photos, converted to JPEG, saved under img/:

  • hero: kpv-hero.jpg — Peptide Works KPV 2 mg vial (peptide-works.com)
  • side: kpv-side.jpg — Licensed Peptides KPV product photo (licensedpeptides.com; replaced a failed pept.au download — no item dropped)
  • detail: kpv-detail.jpg — Purity Peptides KPV 5 mg product image (puritypeptides.is)
  • box: kpv-box.jpg — Prime Science KPV 10 mg product-gallery shot (primescience.co)
  • top: kpv-top.jpg — Pure Health Peptides KPV vial photo (purehealthpeptides.com)

Missing views (honestly not obtainable): rear, inuse (no real owner in-use photos surfaced), scale. No item-specific true kit-box photo was obtainable; the "box" slot holds a distinct vendor product-gallery shot. One candidate (pept.au) failed to download (empty server reply) and was replaced with the Licensed Peptides image.

Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.

KPV — box view
box view Original vendor page URL not recorded in research dossier
KPV — detail view
detail view Original vendor page URL not recorded in research dossier
KPV — hero view
hero view Original vendor page URL not recorded in research dossier
KPV — side view
side view Original vendor page URL not recorded in research dossier
KPV — top view
top view Original vendor page URL not recorded in research dossier

Sources